Business
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer
Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancerMedian Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached]Median Local Progression-Free Survival of 13.3 months from completion of radiationNotable findings observed in exploratory biomarker analyses include: An association between increased circulating tumor mutational burden (cTMB)
About this update from Nanobiotix Sa
[{"type":"image","alt":"Nanobiotix S.A.","displaySize":"","headline":null,"caption":"Nanobiotix S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/ae5026f0933e6f98c5e60a809a606998"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/w.WG45QhRIjOjkLYfarG8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ae5026f0933e6f98c5e60a809a606998","width":300,"height":100}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancer","length":180,"tagName":"p"}]},{"val":[{"type":"text","content":"Median Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached]","length":93,"tagName":"p"}]},{"val":[{"type":"text","content":"Median Local Progression-Free Survival of 13.3 months from completion of radiation","length":82,"tagName":"p"}]},{"val":[{"type":"text","content":"Notable findings observed in exploratory biomarker analyses include:","length":68,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"An association between increased circulating tumor mutational burden (cTMB) and LPFS and OS","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"CA19-9 normalization in 59% of patients in the study, and an association between CA19-9 normalization and OS","length":108,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":199,"olType":false}]},{"val":[{"type":"text","content":"First patient injected in a new cohort that adds standard-of-care concurrent chemotherapy (capecitabine or 5-FU) to radiotherapy-activated JNJ-1900 (NBTXR3) and recruitment is ongoing","length":183,"tagName":"p"}]},{"val":[{"type":"text","content":"Investigators concluded that these results support further evaluation in a randomized study","length":91,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":896,"olType":false},{"type":"text","content":"Data presented at the 2025 Annual Meeting of the European Society of Radiation Oncology","length":87,"tagName":"p"},{"type":"text","content":"PARIS and CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the...